Clinical Trials Logo

Bacteremia clinical trials

View clinical trials related to Bacteremia.

Filter by:

NCT ID: NCT01734694 Terminated - Bacteremia Clinical Trials

Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

STOP-NT
Start date: October 2011
Phase: Phase 4
Study type: Interventional

For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.

NCT ID: NCT01728376 Completed - Bacteremia Clinical Trials

Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)

Start date: November 29, 2012
Phase: Phase 4
Study type: Interventional

The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).

NCT ID: NCT01724671 Not yet recruiting - Pneumonia Clinical Trials

Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline

Start date: December 2012
Phase: N/A
Study type: Observational

To compare the time to pathogen eradication, and the relationship to the time to clinical improvement, between ceftaroline and case-matched vancomycin treated controls in the treatment of adults with serious infections caused by Methicillin-Resistant Staphylococcus aureus (MRSA).

NCT ID: NCT01701219 Completed - Clinical trials for Staphylococcus Aureus Bacteremia

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

Start date: January 2013
Phase: Phase 4
Study type: Interventional

This is a study of safety and efficacy of ceftaroline fosamil in Subjects with Staphylococcus aureus Bacteremia or with Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia persisting after at least 72 hours of vancomycin and/or daptomycin treatment.

NCT ID: NCT01689753 Completed - Clinical trials for Other Complication of Vascular Dialysis Catheter

Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia

Start date: March 2009
Phase: N/A
Study type: Interventional

The aim of the trial was to assess whether use of the TEGO connector was able to reduce the incidence of a composite endpoint of TCC-related dysfunction (TCC-D)or TCC-related bacteremia (TCC-B) in chronic hemodialysis (HD) patients carrying the TEGO® connector vs controls receiving trisodium citrate 46.7%.

NCT ID: NCT01673269 Completed - Cholangiocarcinoma Clinical Trials

Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD

Start date: July 2012
Phase: N/A
Study type: Interventional

When a doctor performs Endoscopic retrograde cholangiopancreatography "ERCP" (Endoscopy to examine the bile duct) a flexible tube is inserted into the mouth and into the stomach. The tube passes beyond the stomach and into an opening in the liver called the bile duct. Another small flexible endoscope is inserted inside the ERCP scope to directly visualize the bile duct to ensure that there are no cancers or stones in the bile duct and occasionally to take a sample from the bile duct. The purpose of our study is to examine wither performing this procedure can transmit bacteria from the bile duct to the main blood stream.

NCT ID: NCT01647347 Completed - Clinical trials for Bacteraemia Post Debridement

PVP Iodine Effect on Post Debridement Bacteraemia

PJB 1
Start date: August 2012
Phase: Phase 4
Study type: Interventional

The study investigates the effect of supra- and subgingival rinsing of 10% PVP prior to ultrasonic debridement in patients with periodontitis (as compared to rinsing with water) in terms of post treatment bacteraemia. Study design: Randomized split-mouth (cross-over) study on 20 generally healthy subjects.

NCT ID: NCT01640886 Terminated - Bacteremia Clinical Trials

Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA

Start date: June 2012
Phase: N/A
Study type: Observational

In vitro identification of S. aureus,methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA)from positive blood culture using MicroPhage's bacteriophage-based diagnostic platform.

NCT ID: NCT01619462 Recruiting - Sepsis Clinical Trials

Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children

PCV1103
Start date: November 2011
Phase: Phase 3
Study type: Interventional

The study aims to evaluate the safety and immunogenicity of the 10-valent and 13-valent pneumococcal conjugate vaccines when administered in an accelerated schedule in Papua New Guinean children, who experience early dense upper respiratory tract colonisation with a broad range of pneumococcal serotypes, and to compare antibody titres following a booster dose of polysaccharide vaccine at 9 months with those children who received no booster at the same age.

NCT ID: NCT01592032 Active, not recruiting - Clinical trials for Catheter-Related Infections

Concentration of Antimicrobials in Catheter-lock Solutions

CONAN
Start date: May 2012
Phase: Phase 4
Study type: Interventional

The antibiotic lock technique (ALT) is used as local treatment for Catheter-Related Bacteremia (CRB). It consists in the administration of a concentrated antimicrobial solution with a calculated volume to fill the lumen of the catheter. The lock solution is indwelled within the catheter for a defined period of hours or days before been removed. Currently, the Infectious Diseases Society of America (IDSA) Guidelines for treatment and management of CRB, recommends to change the antibiotic solution every 24 hours. The investigators expect to determine the stability of the concentration of vancomycin, teicoplanin, linezolid, daptomycin and tigecycline used in lock solutions, and thus to assay the optimal timeframe that the concentration of antibiotic used in lock solution keeps its in vivo antimicrobial activity. Study Hypothesis: An antibiotic lock solution maintains in vivo concentration and antimicrobial activity for at least 10 days after its infusion inside a subcutaneous port catheter.